Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H24N2O2S |
Molecular Weight | 332.46 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)\C=C2/SC(=N)NC2=O
InChI
InChIKey=AKTXOQVMWSFEBQ-LCYFTJDESA-N
InChI=1S/C18H24N2O2S/c1-17(2,3)11-7-10(8-12(14(11)21)18(4,5)6)9-13-15(22)20-16(19)23-13/h7-9,21H,1-6H3,(H2,19,20,22)/b13-9-
Darbufelone mesylate is a dual inhibitor of cellular prostaglandin and leukotriene production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 uM) but is much less potent with PGHS-1 (IC50= 20 uM). Darbufelone is a dual inhibitor of cellular PGF2R and LTB4 production. Darbufelone is orally active and nonulcerogenic in animal models of inflammation and arthritis. Darbufelone mesylate was in phase III clinical trials by Pfizer and Zhuhai United Laboratories for the treatment of rheumatoid arthritis.
Originator
Sources: http://adisinsight.springer.com/drugs/800004636
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11412128 |
0.19 µM [IC50] | ||
Target ID: CHEMBL312 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8295221 |
0.77 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl)phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors. | 2010 Dec 15 |
|
Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro. | 2016 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20352217
Mice were administered Darbufelone by gavage at doses
of 20, 40, and 80 mg/kg/day. When mice are treated with Darbufelone at dosage of 80 mg/kg/day, the tumor volumes decrease in a time-dependent manner. In contrast, lower dose of Darbufelone (20 or 40 mg/kg/day) dos not show any significant inhibition of tumor weight.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11412128
In cyclooxygenase assays following a 15-min incubation of enzyme with inhibitor, darbufelone potently inhibits PGHS-2 (IC(50) = 0.19 uM) but is much less potent with PGHS-1 (IC(50) = 20 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB26843
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
7785
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
72H8H6K34C
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
C109268
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
100000091578
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
C81061
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL275835
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
139226-28-1
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
DTXSID5047247
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY | |||
|
6444826
Created by
admin on Fri Dec 15 16:18:39 GMT 2023 , Edited by admin on Fri Dec 15 16:18:39 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)